In this review:
The 2018 Goodfellow Symposium was held in Auckland in March 2018. Dr Stephen Child, medical specialist from ADHB, discussed smoking cessation in chronic obstructive pulmonary disease (COPD) at a breakfast
session sponsored by Pfizer. COPD is the fourth leading cause of death in New Zealand, after ischaemic heart disease, stroke and lung cancer. Smoking is the most important risk factor for COPD and according to recent data, 15.7% of adults in New Zealand were current smokers in 2016/2017.1 This session focused on smoking cessation intervention in patients with COPD, the role of counselling and support and provided an overview of treatment options for nicotine dependence. The session discussed recent data including the first randomised, placebo-controlled trial of varenicline in patients with mild-to-moderate COPD, and the EAGLES study, which evaluated the neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders.
Download PDF